ArThec S.A. will be represented at Cell & Gene Leaders Live on November 15, 2026, at The Shard in London. Dr. Sławomir Jaros, PhD, EMBA, Co-Founder of ArThec, has been invited to participate as a panellist in the event, held as part of London Life Sciences Week.
The event brings together representatives of the biotechnology industry, clinical research, advanced therapy development and life sciences investment, including speakers from Bayer, Cell and Gene Therapy Catapult, the UK BioIndustry Association (BIA), Ocugen and Aspect Biosystems.
Dr. Jaros will join a panel discussion alongside Dr. Lindsay Davies, CEO of QVance and CSO of NextCell Pharma, moderated by Dr. Simon Boa, Managing Director of Bramble Bio.
From tissue engineering to clinical application
With over 20 years of experience spanning research and development, GMP manufacturing, quality assurance and clinical development, Dr. Jaros contributes to the scientific and strategic development of PEARL, ArThec’s investigational tissue-engineered advanced therapy medicinal product (ATMP).
PEARL is being developed for the treatment of focal, full-thickness articular cartilage defects. The technology combines autologous cartilage tissue and chondrocytes, with the aim of supporting cartilage repair and restoration of the damaged articular surface.
Current development milestones
- First-in-human clinical experience: PEARL has been used in patients under the ATMP Hospital Exemption framework, generating preliminary clinical evidence on safety, feasibility and treatment outcomes, including observations of cartilage repair and graft integration.
- Intellectual property and proprietary technology: The core technology is protected by patents widely granted, including European markets, USA, China, Canada, Israel and Turkey. ArThec is also developing dedicated medical devices to support surgical part of Pearl.
- Manufacturing and clinical development: The PEARL manufacturing approach is designed to accommodate patient-specific production while limiting the complexity associated with prolonged cell expansion. The next development steps include preparations for a randomised, multicentre confirmatory clinical trial and planned regulatory interactions with EMA and FDA.
Meet ArThec in London
Participation in Cell & Gene Leaders Live provides an opportunity to exchange perspectives on the scientific, regulatory and manufacturing challenges associated with bringing tissue-engineered therapies into clinical practice.
ArThec welcomes discussions with investors, clinical and research partners, and organisations involved in ATMP manufacturing and development.
